Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
- 12 February 2021
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 384 (12), 1125-1135
- https://doi.org/10.1056/nejmoa2035807
Abstract
Patients with advanced urothelial carcinoma have poor overall survival after platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor treatment.Keywords
This publication has 26 references indexed in Scilit:
- Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer ModelsCancer Research, 2016
- A novel PI3K/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growthCancer Letters, 2016
- Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer ImmunotherapyFrontiers in Immunology, 2015
- Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapyAnnals of Oncology, 2013
- Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment ApproachesFrontiers in Pharmacology, 2013
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial TractJournal of Clinical Oncology, 2009
- Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urotheliumCancer, 2003
- Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial CancerJournal of Clinical Oncology, 2002
- Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.Journal of Clinical Oncology, 1997